Efficacy and Safety of Canagliflozin Versus Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin (CANTATA-SU): 52 Week Results From a Randomized, Double-Blind, Phase 3 Non-Inferiority Trial

Study Questions:

What are the safety and efficacy of canagliflozin (an inhibitor of the sodium-glucose cotransporter 2, which lowers the renal threshold for glucose) compared with glimepiride as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with metformin?